瑞银:升先声药业(02096.HK)目标价至16.3港元 维持“买入”评级

智通财经
Aug 25
【瑞银:升先声药业(02096.HK)目标价至16.3港元 维持“买入”评级】智通财经APP获悉,瑞银发布研报称,先声药业(02096.HK)中期业绩胜预期,收入及净利润同比增长15.1%及32.2%,略高于该行预测。管理层重申2025年收入及调整后利润至少增长15%的指引,并预测至2027年收入及净利润可达到110亿及20亿元人民币。瑞银将先声药业的目标价从14.5港元上调至16.3港元,维持“买入”评级,下调长期研发开支预测,并将2025至2027年每股盈利预测分别上调1.1%、3.9%及7.4%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10